Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00877448Phase 1Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

Role: lead

NCT03450915Phase 3Completed

A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine

Role: lead

NCT02691130Phase 2Completed

Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults

Role: lead

NCT02293317Phase 2Completed

Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV

Role: lead

NCT01419925Phase 2Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Role: lead

NCT01010737Phase 1Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

Role: lead

NCT01146119Phase 2Completed

Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

Role: lead

All 7 trials loaded